A parallel can be drawn to chimeric antigen receptor (CAR)-T-cell oncologic immunotherapy; once CD19-targeted CAR-T-cell therapy demonstrated remarkable benefit for acute lymphoblastic leukemia, a significant bottleneck for widespread use developed [167,168]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.